Catechol-O-methyltransferase genotype (Val158met) modulates cancer-related fatigue and pain sensitivity in breast cancer survivors

Breast Cancer Research and Treatment

Volumn 133, Issue 2, 2012, Pages 405-412

  Fernández de las Peñas, César ^a   Fernández Lao, Carolina ^b   Cantarero Villanueva, Irene ^b   Ambite Quesada, Silvia ^a   Rivas Martínez, Inés ^a   Del Moral Avila, Rosario ^c   Arroyo Morales, Manuel ^b  

^a UNIVERSIDAD REY JUAN CARLOS   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Cancer survivors; Cervical spine; Fatigue; Genetics; Pain

Indexed keywords

AROMATASE INHIBITOR; CATECHOL METHYLTRANSFERASE; METHIONINE; TAMOXIFEN; VALINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER PAIN; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER SURVIVOR; COMT GENE; DISEASE ASSOCIATION; GENE; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; NECK PAIN; PAIN ASSESSMENT; PAIN THRESHOLD; PIPER FATIGUE SCALE; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RATING SCALE; SHOULDER PAIN; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84863722198     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1757-y     Document Type: Article

References (40)

1. Mannisto P, Kaakkola S (1999) Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51:593-628
2. Strous RD, Bark N, Woerner M, Lachman HM (1997) Lack of association of a functional catechol-O-methyltransferase gene polymorphism in schizophrenia. Biol Psychiatry 41:493-495
3. Syvanen AC, Tilgmann C, Rinne J, Ulmanen I (1997) Genetic polymorphism of catechol-O-methyltransferase (COMT): correlation of genotype with individual variation of SCOMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland. Pharmacogenetics 7:65-71
4. Mao C, Wang XW, Qiu LX, Liao R, Ding H, Chen Q (2010) Lack of association between catechol-O-methyltransferase Val108/158Met polymorphism and breast cancer risk: a meta-analysis of 25, 627 cases and 34, 222 controls. Breast Cancer Res Treat 121:719-725
5. Ding H, Fu Y, Chen W, Wang Z (2010) COMT Val158Met polymorphism and breast cancer risk: evidence from 26 case-control studies. Breast Cancer Res Treat 123:265-270
6. Nagel IE, Chicherio C, Li SC, Von Oertzen T, Sander T, Villringer A, Heekeren HR, Bäckman L, Lindenberger U (2008) Human aging magnifies genetic effects on executive functioning and working memory. Front Hum Neurosci 2:1
7. Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y, Koeppe RA, Stohler CS, Goldman D (2003) Val158 met genotype affects l-opioid neurotransmitter responses to a pain stressor. Science 299:1240-1243
8. Ahles TA, Saykin AJ, Noll WW, Furstenberg CT, Guerin S, Cole B, Mott LA (2003) The relationship of APOE genotype to neu-ropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology 12:612-619
9. Small BJ, Rawson KS, Walsh E, Jim HS, Hughes TF, Iser L, Andrykowski MA, Jacobsen PB (2011) Catechol-O-methyl-transferase genotype modulates cancer treatment-related cognitive deficits in breast cancer survivors. Cancer 117:1369-1376
10. Jim HSL, Donovan KA, Small BJ, Andrykowski MA, Munster PN, Jacobsen PB (2009) Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer 115:1776-1783
11. Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, Johnson DH, Miaskowski C, Scherr SL, Portenoy RK, Vo-gelzang NJ (2000) Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 5:353-360
12. Lawrence DP, Kupelnick B, Miller K, Devine D, Lau J (2004) Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J Natl Cancer Inst Monogr 32:40-50
13. Lauridsen MC, Overgaard M, Overgaard J, Hessov IB, Cris-tiansen P (2008) Shoulder disability and late symptoms following surgery for early breast cancer. Acta Oncol 47:569-575
14. Gartner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H (2009) Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA 302:1985-1992
15. Andrykowski MA, Curran SL, Carpenter JS, Studts JL, Cunningham L, McGrath PC, Sloan DA, Kenady DE (1999) Rheumatoid symptoms following breast cancer treatment: a controlled comparison. J Pain Symptom Manag 18:85-94
16. Gottrup H, Andersen J, Arendt-Nielsen L, Jensen T (2000) Psy-chophysical examination in patients with post-mastectomy pain. Pain 87:275-284
17. Vilholm OJ, Cold S, Rasmussen L, Sindrup SH (2009) Sensory function and pain in a population of patients treated for breast cancer. Acta Anaesthesiol Scand 53:800-806
18. Fernández-Lao C, Cantarero-Villanueva I, Fernández-de-Las- Peñas C, Del-Moral-Avila R, Arendt-Nielsen L, Arroyo-Morales M (2010) Myofascial trigger points in neck and shoulder muscles and widespread pressure pain hyper-sensitivity in patients with post-mastectomy pain: evidence of peripheral and central sensi-tization. Clin J Pain 26:798-806
19. Fernández-Lao C, Cantarero-Villanueva I, Fernández-de-Las- Peñas C, Del-Moral-Avila R, Menjón-Beltrán S, Arroyo-Morales M (2011) Widespread mechanical pain hyper-sensitivity as a sign of central sensitization after breast cancer surgery: comparison between mastectomy and lumpectomy. Pain Med 12:72-78
20. Andresen KG, Kehlet H (2010) Persistent pain after breast cancer treatment: a critical review of risk factors and strategies for prevention. J Pain. doi:10.1016/j.jpain.2010.12.005
21. Barsevick AM, Cleeland CS, Manning DC, O'Mara AM, Reeve BB, Scott JA, Sloan JA (2010) ASCPRO (Assessing Symptoms of Cancer Using Patient-Reported Outcomes). ASCPRO recommendations for the assessment of fatigue as an outcome in clinical trials. J Pain Symptom Manag 39:1086-1099
22. Giacalone A, Polesel J, De Paoli A, Colussi AM, Sartor I, Talamini R, Tirelli U (2010) Assessing cancer-related fatigue: the psychometric properties of the Revised Piper Fatigue Scale in Italian cancer inpatients. Support Care Cancer 18:1191-1197
23. Bijur P, Silveer W, Gallagher JE (2001) Reliability of the visual analogue scale for measurement of acute pain. Acad Emerg Med 8:1153-1157
24. Vanderweeen L, Oostendorp RB, Vaes P, Duquet W (1996) Pressure algometry in manual therapy. Man Ther 1:258-265
25. Chesterson LS, Sim J, Wright CC, Foster NE (2007) Inter-rater reliability of algometry in measuring pressure pain thresholds in healthy humans, using multiple raters. Clin J Pain 23:760-766
26. Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Stat 6:65-70
27. Park JW, Lee KS, Kim JS, Kim YI, Shin HE (2007) Genetic contribution of catechol-O-methyltransferase polymorphism in patients with migraine without aura. J Clin Neurol 3:24-30
28. García-Fructuoso FJ, Lao-Villadóniga JI, Beyer K, Santos C (2006) Relationship between catechol-O-methyltransferase genotypes and fibromyalgia's severity. Rheumatol Clin 2:168-172
29. Khasar SG, Green PG, Miao FJ, Levine JD (2003) Vagal modulation of nociception is mediated by adrenomedullary epineph-rine in the rat. Eur J Neurosci 17:909-915
30. Nackley AG, Tan KT, Fecho K, Flood P, Diatchenko L, Maixner W (2007) Catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both b2-and b3-adrenergic receptors. Pain 128:199-208
31. Diatchenko L, Slade G, Nackley AGI, Bhalang K, Sigurdsson A, Belfer I, Goldman D, Xu K, Shabalina SA, Shagin D, Max MB, Makarov SS, Maixner W (2005) Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 14:135-143
32. Rakvag TT, Klepstad P, Baar C et al (2005) The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 116:73-78
33. Ross JR, Riley J, Taegetmeyer AB, Sato H, Gretton S, du Bois RM, Welsh KI (2008) Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and mul-tidrug resistance-1 gene polymorphisms are associated with central side effects. Cancer 112:1390-1403
34. Kurzrock R (2001) The role of cytokines in cancer-related fatigue. Cancer 92:S1684-S1688
35. Collado-Hidalgo A, Bower JE, Ganz PA, Cole S, Irwin M (2006) Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res 12:2759-2766
36. Maier SF, Watkins L (2003) Immune-to-central nervous system communication and its role in modulating pain and cognition: implications for cancer and cancer treatment. Brain Behav Immun 17(suppl 1):S125-S131
37. Bower JE (2007) Cancer-related fatigue: links with inflammation in cancer patients and survivors. Brain Behav Immun 21:863-871
38. Cantarero-Villanueva I, Fernández-Lao C, Fernández-de-las- Pe-ñas C, Díaz-Rodríguez L, Sanchez-Cantalejo E, Arroyo-Morales M (2011) Associations among musculoskeletal impairments, depression, body image and fatigue in breast cancer survivors within the first year after treatment. Eur J Cancer Care. doi: 10.1111/j.1365-2354.2011.01245.x
39. Hamburg MA, Collins FS (2010) The path to personalized medicine. N Engl J Med 363:301-304
40. Reyes-Gibby CC, Wu X, Spitz M, Kurzrock R, Fisch M, Bruera E, Shete S (2008) Molecular epidemiology, cancer-related symptoms, and cytokines pathway. Lancet Oncol 9:777-785